IntelliProve develops a smartphone-camera software that obtains physiological metrics—heart rate, respiratory rate and stress—using optical face scans, marketed as "digital biopsies." The product is offered as a plug-in solution for digital platforms and apps across digital health, corporate wellbeing and health insurance. It holds CE marking as a medical device and ISO27001 certification. The company works with partners including Het Wit‑Gele Kruis, TU Delft, vzw Zorg‑Saam and imec.istart, and serves clients such as Helan and Neutraal Ziekenfonds Vlaanderen. IntelliProve was founded in 2021 and now operates in Belgium, the Netherlands, the UK, Italy, France, Germany and Denmark. Management says the company will refine the solution further and roll it out across Europe. IntelliProve builds a platform that lets doctors and mental-health practitioners assess patient condition using a conventional smartphone camera and a standard finger pulse oximeter. The software extracts embedded biomarkers — mental state, blood oxygen, respiratory rate and blood pressure — from facial expression, body language and pulse readings using signal processing and computer-vision driven AI. It offers a smartphone app and API to enable readings without wearable connected devices. IntelliProve positions its technology as an initial step toward “digital biopsies” to improve preventative healthcare and patient engagement. The company is still finishing product testing and its software has not yet launched. IntelliProve is led by co-founder and CEO Joeri Tulkens.

Total raised

$2M

Funding rounds

2

Latest round

Seed

Latest activity

Jan 2025